7 Amendments of Christine SCHNEIDER related to 2021/2013(INI)
Amendment 78 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
C a. Whereas many innovations of the pharmaceutical industry are not really offering breakthrough improvements for the patients but are either so-called ‘me- too’ pharmaceuticals, which are just another substance for the same indication without major benefits or offer only minor improvements with significantly higher costs; whereas it would be beneficial for patients if the framework for the pharmaceutical industry in Europe would better incentivize real breakthrough innovations;
Amendment 79 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas the strategy must focus more on the innovative potential of European pharmaceutical research, in particular that conducted by SMEs and MidCaps, in order to strengthen Europe for the future; whereas close links must therefore be established with current and future EU strategies, whilst steps are taken to ensure that no additional administrative burdens are imposed on the undertakings in question;
Amendment 190 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3 a. Calls on the Commission to propose as soon as possible a legal framework to encourage innovation for new antibiotics with incentives either comparable to the area of orphan drugs or paediatrics or new innovative incentives to stimulate innovation to bring new antibiotics the market;
Amendment 218 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Calls on the Commission, where appropriate in dialogue with the Member States, to work on a framework for pharmaceutical legislation and a reimbursement system that favours real breakthrough innovations for patients and incentivizes less so-called ‘me too’ pharmaceuticals which do not have an added value or highly expensive pharmaceuticals that offer only minor improvements for patients;
Amendment 568 #
18 a. Underlines – especially in view of the experiences of the COVID-19 crisis – the importance of drug repurposing as a faster way to new treatment options and therefore demands five years of data protection for valuable innovation on known substance; in addition, underlines that a framework which supports the marketing and use of the drug with the approved new label claim - instead of off- label use - should be urgently considered to make drug repurposing attractive in the EU;
Amendment 596 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Points out that the EU’s open strategic autonomy is linked to the availability of sufficient medicines in all Member States at all times; calls on the Commission, therefore, to diversify and thereby strengthen medicine supply chains and to further develop and expand European production sites for essential medicines, in particular those operated by SMEs and MidCaps; calls on the Commission to develop an early-warning system for medicine shortages which draws on a European information network focusing on supply problems; calls on the Commission to enhance cooperation between the public and private sectors and to monitor industry compliance with the requirement to provide timely and transparent information on the availability of medicines; calls on the Commission to develop a mechanism to safeguard transparency in production and supply chains in emergencies;
Amendment 698 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Calls on the Commission to secure supply chains and Europe's open strategic autonomy by diversifying supply chains for essential medicines and critical product components, focusing also on European production sites for the European pharmaceutical industry, which consists mostly of SMEs and MidCaps, by ensuring that public procurement rules take greater account of this objective and are more conducive to efforts to achieve it;